CNS Pharmaceuticals, Inc. Logo

CNS Pharmaceuticals, Inc.

Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.

CNSP | US

Overview

Corporate Details

ISIN(s):
US18978H1023
LEI:
Country:
United States of America
Address:
2100 WEST LOOP SOUTH, 77027 HOUSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's primary therapeutic focus is on glioblastoma multiforme (GBM), an aggressive and often incurable form of brain cancer. Its development pipeline features anti-cancer drug candidates, including its lead drug Berubicin, which are designed to cross the blood-brain barrier to effectively target brain malignancies. CNS Pharmaceuticals aims to advance transformative therapies through pioneering research to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CNS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CNS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CNS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden
NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy
NWRN
NEXGEL, INC. Logo
Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.
United States of America
NXGL
NEXTBIOMEDICAL Co., Ltd. Logo
Develops polymer-based drug-device solutions for hemostasis and drug delivery worldwide.
South Korea
389650
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden
NXTCL
NextCure, Inc. Logo
Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.
United States of America
NXTC
Niagen Bioscience, Inc. Logo
Develops and commercializes a patented NAD+ precursor for supplements, food, beverage & skincare.
United States of America
NAGE
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea
138610

Talk to a Data Expert

Have a question? We'll get back to you promptly.